Profile
Daniel Faga is identified in SEC filings as serving as the President and Chief Executive Officer of AnaptysBio, Inc., a clinical-stage biotechnology company focused on antibody therapies for inflammation and immuno-oncology. The most recent filing dated 2026-01-08 lists his role at ANAB and notes that total purchases and total sales reported in the filing were $0, indicating no reported insider equity transactions in that filing period.
| Role | Insider |
|---|---|
| Notability | 40/100 |
Board memberships
- AnaptysBio, Inc.
Awards & honors
- Assumed the roles of President and Chief Executive Officer at AnaptysBio, Inc.
- Oversees development of antibody therapies for autoimmune/inflammatory diseases and immuno-oncology programs
- Guides corporate strategy and clinical program execution at a clinical-stage biotech company